EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 396-400

  Jia, Xiao Li ^a   Chen, Gang ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adenosquamous carcinoma; EGFR; Immunohistochemical staining; KRAS; Mutation; Sequencing

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ADULT; AGED; ARTICLE; ASIAN; CANCER SIZE; CANCER STAGING; CHINESE; EXON; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG ADENOSQUAMOUS CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICRODISSECTION; POINT MUTATION; PRIORITY JOURNAL; SMOKING;

CARCINOMA, ADENOSQUAMOUS; CHINA; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MICROARRAY ANALYSIS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN;

EID: 80755190090     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.04.005     Document Type: Article

References (29)

1. Travis W.D., Branbilla E., Muller-Hermelink H.K. World Health Organization classification of tumours, pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, IARC, Lyon, France.
2. Shimizu J., Oda M., Hayashi Y., Nonomura A., Watanabe Y. A clinicopathologic study of resected cases of adenosquamous carcinoma of the lung. Chest 1996, 109:989-994.
3. Riquet M., Perrotin C., Lang-Lazdunski L., Hubsch J.P., Dujon A., Manac'H D., et al. Do patients with adenosquamous carcinoma of the lung need a more aggressive approach?. J Thorac Cardiovasc Surg 2001, 122:618-619.
4. Mitsudomi T., Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007, 98:1817-1824.
5. Tam I.Y., Chung L.P., Suen W.S., Wang E., Wong M.C., Ho K.K., et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006, 12:1647-1653.
6. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13:2890-2896.
7. Kang S.M., Kang H.J., Shin J.H., Kim H., Shin D.H., Kim S.K., et al. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 2007, 109:581-587.
8. Toyooka S., Yatabe Y., Tokumo M., Ichimura K., Asano H., Tomii K., et al. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer 2006, 118:1588-1590.
9. Ishida T., Kaneko S., Yokoyama H., Inoue T., Sugio K., Sugimachi K. Adenosquamous carcinoma of the lung. Clinicopathologic and immunohistochemical features. Am J Clin Pathol 1992, 97:678-685.
10. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
11. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
12. Wu M., Szporn A.H., Zhang D., Wasserman P., Gan L., Miller L., et al. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers. Diagn Cytopathol 2005, 33(4):223-227.
13. Ring B.Z., Seitz R.S., Beck R.A., Shasteen W.J., Soltermann A., Arbogast S., et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol 2009, 22:1032-1043.
14. Mukhopadhyay S., Katzenstein A.L. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011, 35:15-25.
15. Au N.H, Gown A.M., Cheang M., Huntsman D., Yorida E., Elliott W.M., et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004, 12(3):240-247.
16. Wu C.C., Hsu H.Y., Liu H.P., Chang J.W., Chen Y.T., Hsieh W.Y., et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer 2008, 113:3199-3208.
17. Kim Y.T., Kim T.Y., Lee D.S., Park S.J., Park J.Y., Seo S.J., et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer 2008, 59:111-118.
18. Jang T.W., Oak C.H., Chang H.K., Suo S.J., Jung MH EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 2009, 24:48-54.
19. Sasaki H., Endo K., Yukiue H., Kobayashi Y., Yano M., Fujii Y. Mutation of epidermal growth factor receptor gene in adenosquamous carcinoma of the lung. Lung Cancer 2007, 55:129-130.
20. Luciani A., Ascione G., Marussi D., Oldani S., Caldiera S., Bozzoni S., et al. Clinical analysis of multiple primary malignancies in the elderly. Med Oncol 2009, 26:27-31.
21. Uramoto H., Yamada S., Hanagiri T. Clinicopathological characteristics of resected adenosquamous cell carcinoma of the lung: risk of coexistent double cancer. J Cardiothorac Surg 2010, 5:92.
22. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., et al. D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12:6494-6501.
23. Costa D.B., Halmos B., Kumar A., Schumer S.T., Huberman M.S., Boggon T.J., et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007, (4):1680. 1669-1679.
24. Sasaki H., Endo K., Takada M., Kawahara M., Kitahara N., Tanaka H., et al. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007, 58:324-328.
25. Taguchi T., Tsukuda M., Imagawa-Ishiguro Y., Kato Y., Sano D. Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncol Rep 2008, 19:65-71.
26. Sasaki H., Endo K., Takada M., Kawahara M., Tanaka H., Kitahara N., et al. EGFR polymorphism of the kinase domain in Japanese lung cancer. J Surg Res 2008, 148:260-263.
27. Mu X.L., Li L.Y., Zhang X.T., Wang M.Z., Feng R.E., Cui Q.C., et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res 2005, 11:4289-4294.
28. Murray S., Timotheadou E., Linardou H., Vrettou A.V., Kostopoulos I., Skrickova J., et al. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer 2006, 52:225-233.
29. Tanaka T., Matsuoka M., Sutani A., Gemma A., Maemondo M., Inoue A., et al. Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 2010, 126:651-655.